Neoplasms

All Conditions

Symptoms and General Pathology

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Recurrence

Nasopharyngeal Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Disease Attributes

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Camrelizumab and chemotherapy combined with endoscopic surgery

2 cycles Camrelizumab before endoscopic surgery and one year after

Camrelizumab

2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery

Chemotherapy

standard endoscopic surgery for recurrent nasopharyngeal carcinoma

endoscopic surgery

Xiaole Song, MD

Desheng Wang, MD

Haichun Lai, MD

Desheng Wang

Shaopeng Huang

Yongtian Lu

Jingjin Weng, PhD

Shenhong Qu

Jing Ye, MD

Jing Ye

Li Yan, MD

Xiaoshen Wang, PHD

Xinsheng Huang

Hongmeng Yu, MD,PHD

To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

A Prospective, Single-arm, Multi-center Clinical Study of Camrelizumab and Chemotherapy Combined With Endoscopic Surgery in the Treatment of Recurrent Nasopharyngeal Carcinoma

using European Organisation for Research and Treatment of Cancer quality of life questionaire（EORTC QLQ) - C30 version3.0. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

using European Organisation for Research and Treatment of Cancer quality of life questionaire（EORTC QLQ）- H\&N35，All of the scales and single-item measures range in score from 0 to 100. For all the scales and single-items a high score represents a high level of symptomatology or problems.

Using CTCAE Version5.0 to evaluate related adverse effect

Using CTCAE Version5.0 to evaluate immune related adverse effect

the date of first treatment to local failure or death

the date of first treatment to the first recording of disease progression or death from any cause.

negative margin rate according to pathology report

the date of first treatment to distant metastasis or death

Chinese Academy of Medical Sciences

Eye & ENT Hospital of Fudan University

Carcinoma, Squamous Cell

Hypopharyngeal Neoplasms

Hypopharyngeal Cancer

TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or \>75%PR. If not, operation is suggested.

Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.

Toripalimab

Yan Sun, MD

TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or \>75% partial remission )after inductive chemotherapy, CCRT is suggested as the definitive therapy, for the tumor is sensitive to chemotherapy. If the primary tumor shrinks a little or progresses after inductive chemotherapy, operation is suggested as the definitive therapy to get a longer survival.

Inductive chemotherapy plus CCRT or operation is an option of organ preservation for patients of hypopharyngeal carcinoma. Many clinical studies have demonstrated that inductive chemotherapy plus CCRT achieved the same prognosis as total laryngectomy, and minimized the damage of normal tissue. TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or \>75% partial remission )after inductive chemotherapy, CCRT is suggested as the definitive therapy, for the tumor is sensitive to chemotherapy. If the primary tumor shrinks a little or progresses after inductive chemotherapy, operation is suggested as the definitive therapy to get a longer survival. This is a prospective, phase II, cohort study. We designate TPF plus Toripalimab as the inductive regime, expecting a higher complete remission rate and longer PFS and OS. And we replace the CCRT with radiation plus Toripalimab to decrease the adverse events of CCRT.

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study

The data is administered by Peking University Cancer Hospital, the investigators need to request related department for sharing IPD.

Complete remission rate 3 months after treatment

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma	NCT05011227	Recurrent Nasop...	Camrelizumab Chemotherapy endoscopic surg...	18 Years -	Eye & ENT Hospital of Fudan University
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma	NCT05011227	Recurrent Nasop...	Camrelizumab Chemotherapy endoscopic surg...	18 Years -	Eye & ENT Hospital of Fudan University
Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC	NCT04624308	Hypopharyngeal ...	Toripalimab	18 Years - 65 Years	Peking University

Spots Global Cancer Trial Database for inductive chemotherapy